Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
Wien Med Wochenschr
; 170(5-6): 132-140, 2020 Apr.
Article
in En
| MEDLINE
| ID: mdl-31654156
ABSTRACT
BACKGROUND:
AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis.METHODS:
Baseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line in the Austrian cohort of ACTION.RESULTS:
Of 100 patients enrolled in Austria, 98 (98.0%) were evaluable 33/98 (33.7%) biologic naïve and 65/98 (66.3%) with ≥1 prior biologic failure. At baseline, biologic-naïve patients had shorter disease duration and lower concomitant corticosteroid use than biologic-failure patients. Overall crude abatacept retention rate was 60.5% and retention rate was higher in biologic-naïve (65.1%) versus biologic-failure (58.0%) patients. Good/moderate EULAR (European League Against Rheumatism) response rates were 85.7% in biologic-naïve and 100% in biologic-failure patients.CONCLUSIONS:
In the Austrian cohort of ACTION, overall abatacept retention at 2 years was high, with higher retention rates in patients receiving abatacept as an earlier treatment line. Good/moderate EULAR response rate was higher in biologic-failure than in biologic-naïve patients.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Antirheumatic Agents
Type of study:
Observational_studies
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Wien Med Wochenschr
Journal subject:
MEDICINA
Year:
2020
Document type:
Article
Affiliation country:
Austria